List All Renal Cell Carcinoma Trials

Renal Cell Carcinoma


PF-05082566 (4-1BB agonist mAb) for Advanced Cancer or B-Cell Lymphoma (UW10051)
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)

Investigator: Ajay K. Gopal, MD;   Conditions: Non-Hodgkin's Lymphoma (NHL);    Status: Recruiting;   Study ID: NCT01307267

MK-3475 + PegIFN-2b and MK-3475 + Ipilimumab
A Phase I/II Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC)

Investigator: John Thompson, MD;   Conditions: Renal Cell Carcinoma, Melanoma;    Status: Recruiting;   Study ID: NCT02089685

Recombinant Interleukin-15 in Treating Patients With Advanced Solid Tumors
A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer

Investigator: John A. Thompson, MD;   Conditions: Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer;    Status: Recruiting;   Study ID: NCT01727076

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Closed;   Study ID: NCT01988896

Phase III Study of MPDL3280A with Bevacizumab vs. Sunitinib for Untreated Advanced Renal Cell Carcinoma (20151056)
A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination with Bevacizumab versus Sunitinib for Untreated Advanced Renal Cell Carcinoma

Investigator: Scott Tykodi, MD;   Conditions: Renal Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT02420821